Skip to main navigation Skip to search Skip to main content

myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy

Research output: Contribution to journal › Short survey › peer-review

Abstract

New findings (Krishnamurty et al.) implicate a subset of cancer-associated fibroblasts (CAFs) that express leucine-rich repeat containing 15 (LRRC15) in promoting tumor growth in pancreatic adenocarcinoma (PDAC), by suppressing the antitumor immunity of cytotoxic T cells. Genetic ablation of LRRC15+ CAFs resulted in better response to immune checkpoint blockade, suggesting they may be a novel target for therapy.

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalTRENDS IN CANCER
Volume9
Issue number1
DOIs
StatePublished - Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CAFs
  • LRRC15
  • PDAC
  • immune suppression
  • microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy'. Together they form a unique fingerprint.

Cite this